Efficacy of rifaximin compared with ciprofloxacin for the treatment of acute infectious diarrhea: A randomized controlled multicenter study

Gut and Liver

Volumn 4, Issue 3, 2010, Pages 357-362

  Hong, Kyoung Sup ^a   Kim, You Sun ^b   Han, Dong Soo ^c   Choi, Chang Hwan ^d   Jang, Byung Ik ^e   Park, Young Sook ^f   Lee, Kang Moon ^g   Lee, Soo Teik ^h   Kim, Hyun Soo ⁱ   Kim, Joo Sung ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Hanyang University College of Medicine   (South Korea)

^d Chung Ang University College of Medicine   (South Korea)

^e Yeungnam University College of Medicine   (South Korea)

^f Eulji University School of Medicine   (South Korea)

^g The Catholic University of Korea College of Medicine   (South Korea)

^h Chonbuk National University Medical School   (South Korea)

ⁱ Chonnam National University Medical School   (South Korea)

Author keywords

Acute infectious diarrhea; Ciprofloxacin; Rifaximin

Indexed keywords

CIPROFLOXACIN; PLACEBO; RIFAXIMIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FECES ANALYSIS; FEMALE; HUMAN; INFECTIOUS DIARRHEA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WELLBEING;

EID: 77957580225     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2010.4.3.357     Document Type: Article

References (22)

1. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med 1999;340:1525-1532.
2. Yang JR, Wu HS, Chiang CS, Mu JJ. Pediatric campylobacteriosis in northern Taiwan from 2003 to 2005. BMC Infect Dis 2008;8:151.
3. Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA 1999;281:811-817.
4. Cho SH, Shin HH, Choi YH, Park MS, Lee BK. Enteric bacteria isolated from acute diarrheal patients in the Republic of Korea between the year 2004 and 2006. J Microbiol 2008;46:325-330.
5. Chong Y, Lee K, Park YJ, et al. Korean Nationwide Surveillance of Antimicrobial Resistance of bacteria in 1997. Yonsei Med J 1998;39:569-577.
6. Lee K, Kim YA, Park YJ, et al. Increasing prevalence of vancomycin-resistant enterococci, and cefoxitin-, imipenem- and fluoroquinolone-resistant gram-negative bacilli: a KONSAR study in 2002. Yonsei Med J 2004;45:598-608.
7. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994;14:51-56. (Pubitemid 24289441)
8. DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001;33:1807-1815.
9. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006;42:541-547.
10. Taylor DN, Bourgeois AL, Ericsson CD, et al. A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg 2006;74:1060-1066.
11. Peña C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520-524.
12. Ena J, López-Perezagua MM, Martínez-Peinado C, Cia-Barrio MA, Ruíz-López I. Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones. Diagn Microbiol Infect Dis 1998;30:103-107. (Pubitemid 28102864)
13. Kim EC. The analysis of antibiotics resistance 2008. Seoul National University Hospital Infection Control Newsletter 2009;15:5-12.
14. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 2001;33:48-53.
15. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469-2477.
16. Robins GW, Wellington K. Rifaximin: a review of its use in the management of traveller's diarrhoea. Drugs 2005;65:1697-1713.
17. Salix Pharmaceuticals. Xifaxan (rifaximin) tablets [prescribing information]. Palo Alto: Salix Pharmaceuticals, 2004.
18. Martini S, Bonechi C, Corbini G, Donati A, Rossi C. Solution structure of rifaximin and its synthetic derivative rifaximin OR determined by experimental NMR and theoretical simulation methods. Bioorg Med Chem 2004;12:2163-2172.
19. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000;44:2205-2206.
20. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002;14:290-295.
21. De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986;12:979-981.
22. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001;32:331-351.